Tradewinds Capital Management LLC maintained its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 862 shares of the medical equipment provider’s stock at the end of the second quarter. Tradewinds Capital Management LLC’s holdings in Zimmer Biomet Holdings were worth $111,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in ZBH. Parkside Financial Bank & Trust boosted its position in Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 22 shares in the last quarter. Parallel Advisors LLC boosted its position in Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 199 shares in the last quarter. IHT Wealth Management LLC boosted its position in Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 256 shares in the last quarter. Sandy Spring Bank boosted its position in Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock valued at $149,000 after buying an additional 20 shares in the last quarter. Finally, Ledyard National Bank boosted its position in Zimmer Biomet Holdings by 9.3% in the first quarter. Ledyard National Bank now owns 1,293 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 110 shares in the last quarter. 83.62% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Holdings, Inc. (ZBH) opened at 110.13 on Friday. Zimmer Biomet Holdings, Inc. has a 12-month low of $95.63 and a 12-month high of $133.49. The firm has a 50-day moving average price of $125.44 and a 200-day moving average price of $121.28. The stock has a market cap of $22.22 billion, a PE ratio of 31.37 and a beta of 1.20.

Zimmer Biomet Holdings (NYSE:ZBH) last released its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. The business had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.95 billion. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The business’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same period last year, the business earned $2.02 EPS. Analysts forecast that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 22nd will be given a $0.24 dividend. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet Holdings’s dividend payout ratio is currently 27.59%.

ILLEGAL ACTIVITY WARNING: “Tradewinds Capital Management LLC Has $111,000 Position in Zimmer Biomet Holdings, Inc. (ZBH)” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.watchlistnews.com/tradewinds-capital-management-llc-has-111000-position-in-zimmer-biomet-holdings-inc-zbh/1471502.html.

Several equities analysts recently issued reports on the stock. Morgan Stanley boosted their target price on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a research note on Monday, July 17th. Stifel Nicolaus reiterated a “hold” rating and issued a $125.00 target price on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Piper Jaffray Companies reiterated a “buy” rating and issued a $141.00 target price on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Canaccord Genuity reiterated a “buy” rating and issued a $141.00 target price on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. Zimmer Biomet Holdings has a consensus rating of “Hold” and a consensus price target of $137.76.

In related news, insider Sang Yi sold 17,731 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $124.56, for a total transaction of $2,208,573.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Tony W. Collins sold 16,986 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by company insiders.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.